Rokos Capital Management (UK)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Rokos Capital Management (UK)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-330,000	Closed	-$42.1M	–	258
2026 Q1	$42.1M	Buy	+330,000	New	+$41.2M	0.32%	59

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Rokos Capital Management (UK)'s XBI Position: Q1 2026 in Review

Rokos Capital Management (UK) sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 81,960 shares — an estimated $10.2M sold.

Rokos Capital Management (UK) first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $9.99M in Q4 2025. 816 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Rokos Capital Management (UK) reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Rokos Capital Management (UK) sold 81,960 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $10.2M.
Rokos Capital Management (UK) first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
Rokos Capital Management (UK)'s State Street SPDR S&P Biotech ETF position peaked at $9.99M in Q4 2025.
816 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Rokos Capital Management (UK)'s 13F filing for Q1 2026, filed 15 May 2026.